Company intelligence / Profile preview
Stimunity
Paris, Francestimunity.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Stimunity has demonstrated efficacy of its cGAMP-VLP with systemic route of administration in preclinical studies. Their STI-001 compound has shown superiority over chemical approaches in treating distant tumors when combined with immune checkpoint therapy[1][2][4].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- BiologicsVirus-Like Particles (VLPs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Institut CurieInsermUniversity of Oxford
Beyond the preview
Go deeper on Stimunity.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stimunity.